• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

What happened in optometry this week: January 8-January 12


Catch up on what happened in optometry during the week of January 8-January 12.

Catch up with what Optometry Times shared this week:

Vevye (cyclosporine ophthalmic solution) 0.1% is now commercially available in US

By Emily Kaiser Maharjan, Assistant Managing Editor

Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available for purchase in the United States and is backed by a 100% money-back guarantee program. Vevye, which was approved by the FDA in June 2023, is the first and only cyclosporine-based product indicated for the signs and symptoms of dry eye disease (DED). It is a non-preserved, water-free semifluorinated alkane eye drop that is to be instilled twice daily.


AI identifies autism via ERG in the blink of an eye

By David Hutton, Managing Editor, Ophthalmology Times

Artificial intelligence can utilize one flash of light to the eye to unlock myriad mysteries, including offering a quicker and more accurate method of diagnosing autism spectrum disorder (ASD) in children, according to research from the University of South Australia and Flinders University.

Using an electroretinogram (ERG), a diagnostic test that measures the electrical activity of the retina in response to a light stimulus, researchers have deployed AI to identify specific features to classify ASD.


Alcon reports positive results from phase 3 Comet trials of AR-15512 for dry eye

By Emily Kaiser Maharjan, Assistant Managing Editor

Alcon’s phase 3 Comet-2 and Comet-3 trials have met primary end points for safety and efficacy of novel topical drug candidate AR-15512 for dry eye disease (DED), the company reports. Alcon anticipates filing a new drug application (NDA) with the US FDA in mid-2024.


Adjunct role for Dextenza insert in allergic conjunctivitis?

By Shani Reich, MD

Allergic conjunctivitis, a prevalent allergen-induced inflammatory-mediated condition, places a significant burden on patients and health care practices. Unfortunately, current topical drop therapies have limitations, including potential for noncompliance and toxicity due to preservatives that can wreak havoc on the ocular surface.


Bausch + Lomb, Glaucoma Research Foundation launch collaborative glaucoma campaign

One of the world’s leading eye care companies and a national nonprofit committed to curing glaucoma have teamed up to launch an awareness campaign to support research for a potential cure.

Bausch + Lomb Corporation and Glaucoma Research Foundation (GRF) announced in a press release that its “The Faces of Glaucoma” campaign will feature educational and diverse patient stories in an effort to raise awareness of the disease through the month of January, which is also Glaucoma Awareness Month.


Related Videos
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
© 2024 MJH Life Sciences

All rights reserved.